Details for Patent: 7,153,825

Title:	Methods for glucagon suppression using modified exendins
Abstract:	We claim a method of lowering plasma glucagon in a subject in need thereof comprising administering to the subject a composition comprising a modified exendin or modified exendin analog, wherein said modification comprises one or more molecule linked to an exendin or the exendin analog wherein said molecule is selected from the group consisiting of polyethylene glycol, gelatin and/or albumin. The modified exendin or the modified exendin analog has activity of suppressing glucagon secretion and/or lowering glucagon levels in the subject and possesses increased biological half-life compared to unmodified exendin or unmodified exendin analog. The method is useful in treating hyperglucagonemia and other disorders that would be benefited by lowering plasma glucagon or suppressing glucagon secretion.
Inventor(s):	Young; Andrew A. (Rancho Santa Fe, CA), Gedulin; Bronislava (San Diego, CA)
Assignee:	Amylin Pharmaceuticals, Inc. (San Diego, CA)
Filing Date:	Mar 18, 2005
Application Number:	11/083,730
Claims:	1. A method of lowering plasma glucagon in a subject in need thereof, comprising: identifying a subject in need of therapeutic lowering of plasma glucagon levels; and administering to said subject a composition comprising a therapeutically effective glucagon lowering amount of a modified exendin, a modified exendin analog or any combination thereof; wherein said modified exendin and modified exendin analog each have an amino acid sequence that is mom than 30 amino acid residues in length; wherein said modified exendin and modified exendin analog each have a half-life that is at least about 10% greater than the half-life of an unmodified exendin and unmodified exendin analog, respectively; and wherein said modification comprises one or mom molecules linked to an exendin or exendin analog, wherein said molecule is selected from the group consisting of polyethylene glycol, gelatin and albumin, and said modification increases the molecular weight of said exendin or exendin analog by at least 10% as compared to the exendin or exendin analog without said one or more molecules. 2. The method of claim 1, wherein said one or more molecules comprises between 1 and 3 molecules. 3. The method of claim 1, wherein said one or more molecules comprises one or more polymers of polyethylene glycol. 4. The method of claim 1, wherein each of said one or more molecules has a molecular weight of from about 500 to about 20,000. 5. The method of claim 1, wherein said one or more molecules is linked to an exendin or exendin analog at an amino, carboxyl, thiol group, diamine or dicarboxylic group. 6. The method of claim 1, wherein said one or more molecules is linked to exendin or exendin analog at a side chain of a lysine, aspartic acid, glutamic acid or cysteine. 7. The method of claim 1, wherein said one or more molecules is linked to said exendin or exendin analog at the epsilon amino group of a lysine. 8. The method of claim 1, wherein said subject is suffering from necrolytic migratory erythema. 9. The method of claim 1, wherein said subject has a glucagonoma. 10. The method of claim 1, wherein said subject has a diabetes. 11. The method of claim 10, wherein said subject has type II diabetes. 12. The method of claim 1, wherein said subject is a human. 13. The method of claim 1, further comprising administering an additional anti-glucagon agent. 14. The method of claim 13, wherein said additional anti-glucagon agent is provided in a single composition or solution for administration with said composition comprising a therapeutically effective glucagon lowering amount of a modified exendin, a modified exendin analog or any combination thereof. 15. The method of claim 13, wherein said additional anti-glucagon agent is an amylin or amylin agonist. 16. The method of claim 1, wherein said administering is by injection, nasal administration, tracheal administration, pulmonary administration, sublingual administration, by gavage or intraduodenal administration. 17. The method of claim 1, wherein said glucagon lowering amount is between about 0.01 mg/day and about 5 mg/day. 18. The method of claim 1, wherein said glucagon lowering amount is between about 0.01 mg/day and about 1 mg/day. 19. The method of claim 1, wherein said composition comprises at least one exendin analog having an amino acid sequence selected from the group consisting of any one of sequences of SEQ ID NOs. 1 40. 20. The method of claim 1, wherein said composition comprises at least one exendin analog comprising SEQ ID NO.41. 21. The method of claim 1, wherein said composition comprises at least one exendin analog comprising SEQ ID NO.42. 22. The method of claim 1, wherein said composition comprises at least one exendin analog comprising SEQ ID NO.43. 23. The method of claim 1, wherein said composition comprises at least one exendin analog comprising SEQ ID NO.44. 24. The method of claim 1, wherein said composition comprises at least one exendin analog comprising SEQ ID NO.45. 25. The method of claim 1, wherein said composition comprises at least one exendin analog comprising SEQ ID NO.46. 26. The method of claim 1, wherein said composition comprises at least one exendin analog comprising SEQ ID NO.47. 27. The method of claim 1, wherein said composition comprises at least one exendin analog comprising SEQ ID NO.48. 28. The method of claim 1, wherein said composition comprises a modified exendin or modified exendin analog selected from any one of the group consisiting of SEQ ID NOs.223 239. 29. A method of lowering plasma glucagon in a subject in need thereof, comprising: identifying a subject in need of therapeutic lowering of plasma glucagon levels; and administering to said subject a composition comprising between about 0.01 mg/day and about 5 mg/day of modified exendin analog or any combination thereof wherein said modified exendin and modified exendin analog each have an amino acid sequence that is more than 30 amino acid residues in length; wherein said modified exendin and modified exendin analog each have a half-life that is at leas-t about 10% greater than the half-life of an unmodified exendin and unmodified exendin analog; and wherein said modification comprises one or more polyethylene glycol polymers having a molecular weight of from About 500 to about 20,000 linked to an exendin or exendin analog. 30. The method of claim 29, wherein said subject is suffering from necrolytic migratory erythema. 31. The method of claim 29, wherein said subject has a glucagonoma. 32. The method of claim 29, wherein said subject has a diabetes. 33. The method of claim 1, wherein said modification comprises one or more albumin molecules. 34. The method of claim 1, wherein said modified exendin is albumin-modified exendin-4 [SEQ ID NO.2]. 35. The method of claim 29, wherein said exendin is exendin-4 [SEQ ID NO.2].